(Q43272312)

18 November 2017

title

Phase II trial of mirtazapine for cancer-related cachexia and anorexia (English)

1 reference

18 November 2017

main subject

phase II clinical trial

0 references

3

Ian F Tannock

1 reference

18 November 2017

Rachel P Riechelmann

1

1 reference

18 November 2017

Debika Burman

series ordinal

2

1 reference

18 November 2017

Gary Rodin

series ordinal

4

1 reference

18 November 2017

Camilla Zimmermann

series ordinal

5

1 reference

18 November 2017

publication date

23 September 2009

1 reference

American Journal of Hospice and Palliative Medicine

18 November 2017

published in

1 reference

18 November 2017

volume

27

1 reference

18 November 2017

issue

2

1 reference

18 November 2017

page(s)

106-110

1 reference

The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Appetite and cancer-associated anorexia: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Cancer cachexia: the molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Should cancer patients with incurable disease receive parenteral or enteral nutritional support?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Tolerability and safety aspects of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

A Review of the Pharmacological and Clinical Profile of Mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Body weight changes associated with psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Clinical pharmacokinetics of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

A diagnostic interview: the schedule for affective disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Systematic review of the treatment of cancer-associated anorexia and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1049909109345685

21 January 2018

Identifiers

DOI

10.1177/1049909109345685

1 reference

18 November 2017

1 reference